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Remarkable progress has been made in using genomic
information to determine how genes are regulated, and
how they interact with each other and with the environ-
ment to control complex biochemical functions of living
organisms in health and disease [1]. This information
will have major benefits for the prevention, diagnosis
and management of many diseases, including commu-
nicable and genetic diseases. In Africa, where infectious
diseases are highly prevalent, research on pathogen ge-
nomes has enhanced our understanding of disease trans-
mission, virulence mechanisms and avoidance of host
defenses [2]. It is anticipated that this information will
enable the development of new diagnostic tests, vaccines
and therapeutic agents; it is also likely to lead to new ap-
proaches for vector control, and reveal why individuals
and populations vary in their susceptibility to infectious
diseases [1].
This commentary focuses on problems and prospects
for the use of new genomic knowledge in improving
the health of Africans. The prospects for genomic medi-
cine in Africa have been enhanced by major initiatives
that are led by international funding agencies and
academics, such as the Malaria Genomic Epidemiology
Network (MalariaGEN) (www.malariagen.net/) and
the Human Heredity and Health in Africa (H3Africa)
program (h3africa.org/h3africa_whitepaper.pdf ). These
multi-national consortia have started to build the
capacity in research skills and overcome the barriers for
the use of genomics to address the disease burden of
Africans. The time has come for African governments
to heed the call of the World Health Organization to
embrace genomics for the benefit of their populations.* Correspondence: ambroise.wonkam@uct.ac.za
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There is a danger that new developments in genomics
will increase the disparity in healthcare within countries,
and between developed and developing countries, due to
the high cost of implementing research findings in the
clinic [1]. Inequalities in healthcare may be further exac-
erbated by the current intellectual property regime un-
less care is taken to ensure that knowledge produced
through genomics research becomes a public good [3].
Furthermore, the limited biotechnology and information
technology infrastructure in many African countries hin-
ders the participation of researchers and clinicians in
genomic medicine. There is a lack of market incentives
for the private sector to invest in genomics research di-
rected towards neglected diseases of the world’s poorest
people. Therefore, the potential for genomics research to
combat these diseases will only be realized through an
enforceable global mechanism for public investment in
health research on such diseases [3]. Indeed, more than
one billion people in developing countries suffer from
one or more neglected infectious diseases, most of which
are found in Africa. Battling neglected infectious
diseases is an important priority of the Bill & Melinda
Gates Foundation (www.gatesfoundation.org), which has
committed more than US$1.02 billion for research on
methods of treatment and prevention, using genomic
technologies in some cases.
Finally, the high cost of genomics and lack of techno-
logical capacity is compounded by a relatively low level
of public and professional understanding of genomics in
African countries [4]. There is, therefore, a need for Af-
rican societies to prepare for the genomics era and its
consequences through education at all levels, with par-
ticular emphasis on improving science education and
the introduction of the principles of biomedical ethics to
school children [1]. H3Africa draws increased attention
to a number of longstanding and emerging issues in
genetic and genomic research, such as informed consent,
community engagement, privacy and confidentiality, use
of genetic information, governance of biorepositories,Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sults and incidental findings. These issues are high-
lighted by genome-wide association studies or whole
exome/genome sequencing that will be carried out in
many projects. Unfortunately, there is a dearth of pub-
lished research on the views of Africans and African
communities concerning participation in genomic re-
search, and virtually no information on their perspec-
tives regarding several of these issues [4].
The prospects
Simple clinical applications of DNA technology could
provide immediate benefit for healthcare in many Afri-
can countries. For example, sickle cell disease (SCD), an
inherited condition, imposes a heavy economic burden
on health systems in Africa, with nearly two-thirds of
the 305,800 infants born annually with SCD worldwide
living in Africa [5]. Prenatal genetic diagnosis of SCD
would allow the option of termination of pregnancy. In
Cameroon, despite the fact that the majority of doctors
and parents of SCD children and adult SCD patients
agreed with the principle of testing for prenatal genetic
diagnosis of SCD (78.7%, 89.8% and 89.2%, respectively),
parents (62.5% acceptance) were more in favor of ter-
mination of an SCD-affected pregnancy than doctors
and adult patients (36.1% and 40.9% acceptance, respect-
ively) [6]. These preliminary data signal potential value-
based conflicts, and can inform concrete future policy
interventions as genomic medicine is increasingly em-
ployed in African countries. Genomic data can also be
used in secondary prevention of SCD, and African re-
searchers are participating actively in producing clinic-
ally relevant genetic research on SCD. For example, a
study from Tanzania has confirmed that polymorphisms
in BCL11A and HBS1L-MYB genes modulate fetal
hemoglobin (HbF) levels and thereby modify the severity
of SCD [7]. Identifying loci that affect HbF levels could
be used to predict an individual’s ability to produce HbF
from birth, and prepare a treatment regimen to reduce
the severity of SCD. As genomic technology advances,
the values and practices of health professionals and
community members must be studied in order to ensure
culturally appropriate and cost-effective implementation
of strategies to improve awareness and early detection,
and prevention of complications of SCD [6].
Although there is sporadic evidence of participation of
Africans in researching the genomics of rare monogenic
[8] and multifactorial conditions [9], there is little evi-
dence that this improved contribution of African re-
searchers to research has an impact on wider public
understanding of, attitudes to, and understanding of
genomic medicine. The area where there has been the
greatest contribution is in the understanding of the gen-
omic basis of malaria through MalariaGEN, which bringstogether researchers from 21 countries in Africa and
elsewhere [10]. MalariaGEN has made major contribu-
tions to overcoming the scientific, ethical and practical
challenges to carrying out such studies in Africa where
the burden of malaria is greatest. The achievements of
MalariaGEN include: analysis of 86,158 exonic single nu-
cleotide polymorphisms in 227 samples, which has
allowed the establishment of an open-access web appli-
cation for the exploration of regional differences in allele
frequency and of highly differentiated loci in the Plasmo-
dium falciparum genome [10]; reviewing the methodo-
logical challenges of genome-wide association studies in
Africa, and how these studies will be transformed by
new approaches in statistical imputation and large-scale
genome sequencing; the exploration of achieving valid
consent both from the perspective of protecting individ-
uals and building trust between communities and re-
search groups, and recommendations of ethical data-
release policies that provide adequate protection for
the research aspirations of developing country scientists
(http://www.sanger.ac.uk/research/initiatives/globalhealth/
partnerships/malariagen.html).
The prospects for genomic medicine in Africa have
been given a major boost by the US National Institutes
of Health and the Wellcome Trust, which are investing
approximately US$37 million in the H3Africa program
over 5 years. The H3Africa consortium has three major
goals: to increase the number of African scientists
who are internationally competitive in genomics and
population-based research; to establish collaborative net-
works of African investigators pursuing genomics-based
disease-oriented projects on conditions that are preva-
lent in Africa; and to create and expand the infrastruc-
ture for genomics research, including bioinformatics and
biorepositories on the African continent (http://h3africa.
org/h3africa_whitepaper.pdf ). This initiative, which was
conceived by the African Society of Human Genetics, is
set to expand the capacity of African institutions to
undertake research in genomic medicine over the next
decade.
A call to action
Improved capabilities of African institutions to under-
take research will be realized if ministries of health im-
plement at least three of the key recommendations of
the World Health Organization Report on Genomics
and World Health [1]. First, capacity building will be
achieved most effectively through the development of
academic public research and industrial partnerships
between developed and developing countries and be-
tween developing countries themselves, encouraged by
tax or other incentives, and through extensive network-
ing within regions where there is evolving expertise
in biotechnology. The H3Africa program has planted
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tured by African governments to ensure the long-term
sustainability of genomic medicine on the continent.
Second, to be able to utilize the vast quantities of gen-
omic data that are being generated, African countries
must develop a critical mass of expertise in bioinformat-
ics. There is already a shortage of trained scientists and
technicians in this crucially important discipline, even in
developed countries. As a first step, countries may de-
cide to examine their current capacity in bioinformatics
and identify existing shortfalls. Finally, all African coun-
tries need to evolve appropriate national frameworks to
consider the ethical implications of genomics research
and its applications in their own unique social, cultural,
economic and religious context; empirical data from a
broad spectrum of stakeholders and the public are
needed for the development of effective genomic policies
and programs of disease that affect the continent.
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